EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest

Serena Mancarella, Isabella Gigante, Elena Pizzuto, Grazia Serino, Alberta Terzi, Francesco Dituri, Eugenio Maiorano, Leonardo Vincenti, Mario De Bellis, Francesco Ardito, Diego F Calvisi, Gianluigi Giannelli

Journal of Experimental & Clinical Cancer Research · 2024

DOI: 10.1186/s13046-024-03210-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental & Clinical Cancer Research, 2024. Verfasst von Serena Mancarella und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, Castellana Grotte, BA, 70013, Italy. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Cancer-Associated Fibroblasts, Cell Cycle Checkpoints. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer-associated fibroblasts (CAFs), mainly responsible for the desmoplastic reaction hallmark of intrahepatic Cholangiocarcinoma (iCCA), likely have a role in tumor aggressiveness and resistance to therapy, although the molecular mechanisms involved are unknown. Aim of the study is to investigate how targeting hCAF/iCCA cross-talk with a Notch1 inhibitor, namely Crenigacestat, may affect cancer progression.

Methods

We used different in vitro models in 2D and established new 3D hetero-spheroids with iCCA cells and human (h)CAFs. The results were confirmed in a xenograft model, and explanted tumoral tissues underwent transcriptomic and bioinformatic analysis. Results hCAFs/iCCA cross-talk sustains increased migration of both KKU-M213 and KKU-M156 cells, while Crenigacestat significantly inhibits only the cross-talk stimulated migration. Hetero-spheroids grew larger than homo-spheroids, formed by only iCCA cells. Crenigacestat significantly reduced the invasion and growth of hetero- but not of homo-spheroids. In xenograft models, hCAFs/KKU-M213 tumors grew significantly larger than KKU-M213 tumors, but were significantly reduced in volume by Crenigacestat treatment, which also significantly decreased the fibrotic reaction. Ingenuity pathway analysis revealed that genes of hCAFs/KKU-M213 but not of KKU-M213 tumors increased tumor lesions, and that Crenigacestat treatment inhibited the modulated canonical pathways. Cell cycle checkpoints were the most notably modulated pathway and Crenigacestat reduced CCNE2 gene expression, consequently inducing cell cycle arrest. In hetero-spheroids, the number of cells increased in the G2/M cell cycle phase, while Crenigacestat significantly decreased cell numbers in the G2/M phase in hetero but not in homo-spheroids.

Conclusions

The hCAFs/iCCA cross-talk is a new target for reducing cancer progression with drugs such as Crenigacestat. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaCancer-Associated FibroblastsCell Cycle CheckpointsHumansAnimalsMiceBile Duct NeoplasmsCell Line, TumorXenograft Model Antitumor AssaysDisease Progression

Stichwörter der Autor:innen

Cholangiocarcinoma progressionGamma secretase inhibitorLiver cancerTumor microenvironmentTumor stroma

Autor:innen und Institutionen

  • National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, Castellana Grotte, BA, 70013, Italy.
  • Division of General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Gynecology and Pediatrics, University of Verona, G.B. Rossi University Hospital, P.le L.A. Scuro 10, Verona, 37134, Italy.
  • Hepatobiliary Surgery Unit, Foundation "Policlinico Universitario A. Gemelli", IRCCS, Catholic University, Rome, Italy.
  • Institute of Pathology, University of Regensburg, 93053, Regensburg, Germany.
  • National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, Via Turi 27, Castellana Grotte, BA, 70013, Italy. gianluigi.giannelli@irccsdebellis.it.

Förderung

  • Fondazione AIRC per la ricerca sul cancro ETS
  • Ministero della Salute

Zitieren

APA

Mancarella, S., Gigante, I., Pizzuto, E., Serino, G., Terzi, A., Dituri, F., Maiorano, E., Vincenti, L., De Bellis, M., Ardito, F., Calvisi, D. F., & Giannelli, G. (2024). Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-024-03210-9

Vancouver

Mancarella S, Gigante I, Pizzuto E, Serino G, Terzi A, Dituri F, et al. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest. Journal of Experimental & Clinical Cancer Research. 2024. doi:10.1186/s13046-024-03210-9

BibTeX
@article{Mancarella2024,
  author = {Mancarella, Serena and Gigante, Isabella and Pizzuto, Elena and Serino, Grazia and Terzi, Alberta and Dituri, Francesco and Maiorano, Eugenio and Vincenti, Leonardo and De Bellis, Mario and Ardito, Francesco and Calvisi, Diego F and Giannelli, Gianluigi},
  title = {Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest},
  journal = {Journal of Experimental & Clinical Cancer Research},
  year = {2024},
  doi = {10.1186/s13046-024-03210-9}
}
Kostenlos starten →